An expert consensus on prevention, diagnosis, and management of hemorrhagic cystitis in pediatric hematopoietic cell transplantation, on behalf of the Infectious Disease and Hematopoietic Cell Transplant Working groups of Italian Pediatric Hematology Oncology Association (AIEOP)

The optimal management of hemorrhagic cystitis (HC) in hematopoietic stem cell transplantation (HCT) is debated, both for early onset HC (EOHC) secondary to chemotherapy toxicity and BK Polyomavirus (BKPyV)-related HC, due to the lack of controlled trials, particularly referred to pediatric setting....

Full description

Saved in:
Bibliographic Details
Published in:Bone marrow transplantation (Basingstoke) 2024-09, Vol.59 (9), p.1302-1308
Main Authors: Dell’Orso, Gianluca, Carlucci, Marcello, Cesaro, Simone, Olcese, Evelina, Balduzzi, Adriana, Vendemini, Francesca, Catti, Massimo, Saglio, Francesco, Compagno, Francesca, Maximova, Natalia, Rabusin, Marco, Menconi, Maria Cristina, Perruccio, Katia, Soncini, Elena, Tambaro, Francesco Paolo, Tintori, Veronica, Pagliara, Daria, Faraci, Maura
Format: Article
Language:English
Subjects:
Best practice
Chemotherapy
Clinical trials
Cystitis
Diagnosis
Disease management
Epidemiology
Guidelines
Hematopoietic stem cells
Hemorrhagic cystitis
Infectious diseases
Leukemia
Oncology
Pathogenesis
Pediatrics
Prevention
Risk factors
Stem cell transplantation
Stem cells
Toxic diseases
Toxicity
Transplantation
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The optimal management of hemorrhagic cystitis (HC) in hematopoietic stem cell transplantation (HCT) is debated, both for early onset HC (EOHC) secondary to chemotherapy toxicity and BK Polyomavirus (BKPyV)-related HC, due to the lack of controlled trials, particularly referred to pediatric setting. Actually, clinical practice is mainly based on guidelines of the European Conference on Infections in Leukemia, 6th edition, which considers both adult and pediatric populations but concludes that, despite much progress in understanding the pathogenesis, epidemiology, and risk factors, this complication still represents a disabling unmet clinical need with limited prophylactic and therapeutic options. Additionally, the Guidelines of the American Society of Clinical Oncology define the management of chemotherapeutic toxicity independently from the patients’ population. A panel of experts belonging to the Hematopoietic Cell Transplant and Infectious Disease Working Group (WG) of Associazione Italiana di Emato-Oncologia Pediatrica (AIEOP) developed a consensus to define the best practices in prevention, diagnosis, and management of HC in pediatric HCT setting.
ISSN:0268-3369
1476-5365
1476-5365
DOI:10.1038/s41409-024-02320-4